Voyager Therapeutics
VYGR
110 hedge funds and large institutions have $300M invested in Voyager Therapeutics in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 40 reducing their positions, and 17 closing their positions.
3% less funds holding
Funds holding: 113 → 110 (-3)
5.23% less ownership
Funds ownership: 80.23% → 75% (-5.2%)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
20% less capital invested
Capital invested by funds: $377M → $300M (-$77M)
40% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 40
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.69M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.65M |
| 4 |
NIM
Needham Investment Management
New York
|
+$880K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$580K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$9.46M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.4M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.99M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.98M |
| 5 |
Goldman Sachs
New York
|
-$1.86M |
VYGR Hedge Fund Activity: Q3 2020 in Review
110 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2020, worth a combined $300M — down 20% from $377M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VYGR and 14 opened new positions — a net loss of 3 holders — while 40 trimmed existing stakes and 24 added.
The largest buyer was Armistice Capital, adding an estimated $7.3M. The largest seller was Casdin Capital, exiting entirely with an estimated $9.46M sold.
- 110 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2020, down from 113 in Q2 2020.
- Funds reported $300M of Voyager Therapeutics stock for Q3 2020, down 20% quarter-over-quarter.
- 14 funds opened new Voyager Therapeutics positions in Q3 2020 and 17 closed out, a net change of -3 holders.
- The largest Voyager Therapeutics buyer in Q3 2020 was Armistice Capital, an estimated $7.3M added.
- The largest Voyager Therapeutics seller in Q3 2020 was Casdin Capital, an estimated $9.46M sold.
Based on aggregated 13F filings for Q3 2020.